IMPACT BIOMEDICAL INC (IBO) Stock Price, Forecast & Analysis

NYSEARCA:IBO • US45259L2051

0.4414 USD
+0 (+0.32%)
Last: Feb 18, 2026, 04:50 PM

IBO Key Statistics, Chart & Performance

Key Statistics
Market Cap46.18M
Revenue(TTM)7.00K
Net Income(TTM)-38.47M
Shares104.62M
Float11.19M
52 Week HighN/A
52 Week LowN/A
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-3.58
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2024-09-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
IBO short term performance overview.The bars show the price performance of IBO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

IBO long term performance overview.The bars show the price performance of IBO in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of IBO is 0.4414 USD. In the past month the price decreased by -3.79%.

IMPACT BIOMEDICAL INC / IBO Daily stock chart

IBO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
IBO Full Technical Analysis Report

IBO Financial Highlights

Over the last trailing twelve months IBO reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS decreased by -509.26% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -201.86%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-1423.03%
Sales Q2Q%N/A
EPS 1Y (TTM)-509.26%
Revenue 1Y (TTM)N/A
IBO financials

IBO Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
IBO Analyst EstimatesIBO Analyst Ratings

IBO Ownership

Ownership
Inst Owners0.51%
Ins Owners0.43%
Short Float %2.14%
Short Ratio1.99
IBO Ownership

IBO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO30.41979.461B
JNJ JOHNSON & JOHNSON21.03586.255B
MRK MERCK & CO. INC.22.49301.739B
PFE PFIZER INC9.11155.618B
BMY BRISTOL-MYERS SQUIBB CO9.82122.858B
ZTS ZOETIS INC18.855.333B
RPRX ROYALTY PHARMA PLC- CL A8.7426.212B
VTRS VIATRIS INC6.3518.129B
ELAN ELANCO ANIMAL HEALTH INC23.712.352B
AXSM AXSOME THERAPEUTICS INC225.589.24B

About IBO

Company Profile

IBO logo image Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.

Company Info

IMPACT BIOMEDICAL INC

1400 Broadfield Blvd., Suite 130

Houston TEXAS US

Employees: 2

IBO Company Website

IBO Investor Relations

Phone: 15852321500

IMPACT BIOMEDICAL INC / IBO FAQ

What does IMPACT BIOMEDICAL INC do?

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.


What is the current price of IBO stock?

The current stock price of IBO is 0.4414 USD. The price increased by 0.32% in the last trading session.


Does IBO stock pay dividends?

IBO does not pay a dividend.


What is the ChartMill rating of IMPACT BIOMEDICAL INC stock?

IBO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the market capitalization of IBO stock?

IMPACT BIOMEDICAL INC (IBO) has a market capitalization of 46.18M USD. This makes IBO a Nano Cap stock.